Theranostics: are we there yet?

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• The National Cancer Institute aims to eliminate cancer by 2015.
• Nanotechnology-based therapeutics are crucial for achieving this goal.
• Theranostic nanocarriers integrate diagnostic and therapeutic functions.

Purpose of the Study:

• To evaluate different theranostic nanocarrier approaches for cancer therapy.
• To determine the most promising strategies for clinical translation.
• To assess the advantages of polymer-based nanocarriers.

Main Methods:

• Review of various nanocarrier delivery systems (prodrugs, liposomes, polymersomes, micelles, nanoparticles).
• Analysis of agent conjugation and entrapment methods.
• Comparison of passive and active targeting strategies.

Main Results:

• Carefully designed polymers offer advantages for theranostic nanocarrier development.
• Passive targeting via the EPR effect is dominant in current nanocarrier formulations.
• The necessity of active targeting ligands for EPR-effect-based nanocarriers requires further demonstration.

Conclusions:

• While no single approach guarantees immediate clinical success, advanced polymer-based theranostic nanocarriers show significant potential.
• Further research is needed to optimize nanocarrier design for enhanced efficacy and regulatory approval.
• Promising nanotechnology-based approaches are being developed for improved cancer patient outcomes.